Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.

Koh YW, Park YS, Ryu MH, Ryoo BY, Park HJ, Yook JH, Kim BS, Kang YK.

Am J Surg Pathol. 2013 Jul;37(7):1022-9. doi: 10.1097/PAS.0b013e31828778fd.

PMID:
23715160
2.

Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.

Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H.

Ann Surg. 2011 May;253(5):934-9. doi: 10.1097/SLA.0b013e318216f449.

PMID:
21490451
3.

Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.

Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T.

Ann Surg Oncol. 2012 Jun;19(6):1936-43. doi: 10.1245/s10434-011-2165-6. Epub 2011 Dec 21.

PMID:
22187120
4.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
5.

[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].

Yang ZJ, Wei RJ, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2012 Dec;47(12):898-904. Chinese.

PMID:
23324188
6.

Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?

Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG.

Ann Surg Oncol. 2007 Dec;14(12):3412-8. Epub 2007 Oct 2.

PMID:
17909917
7.

Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.

Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K.

Ann Surg Oncol. 2012 Jul;19(7):2119-27. doi: 10.1245/s10434-012-2254-1. Epub 2012 Mar 7.

PMID:
22395980
8.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

PMID:
27298411
9.

Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.

Persiani R, D'Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, Ricci R, La Torre G, Picciocchi A.

J Surg Oncol. 2005 Mar 15;89(4):227-36; discussion 237-8.

PMID:
15726615
10.

Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.

Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Tani T, Fujimura T, Ohta T.

J Surg Oncol. 2012 May;105(6):535-41. doi: 10.1002/jso.22125. Epub 2011 Oct 17.

PMID:
22006649
11.

Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31.

PMID:
9554929
13.

Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.

Jin H, Zhang G, Liu X, Liu X, Chen C, Yu H, Huang X, Zhang Q, Yu J.

World J Surg Oncol. 2013 May 24;11:112. doi: 10.1186/1477-7819-11-112.

14.

Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

Wang LB, Teng RY, Jiang ZN, Hu WX, Dong MJ, Yuan XM, Chen WJ, Jin M, Shen JG.

J Surg Oncol. 2012 Mar;105(3):293-6. doi: 10.1002/jso.22085. Epub 2011 Aug 31.

PMID:
21882201
15.

Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.

Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H, Mochiki E.

Ann Surg Oncol. 2015 Oct;22(11):3618-24. doi: 10.1245/s10434-015-4422-6. Epub 2015 Feb 7.

PMID:
25663597
16.

Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.

Quero L, Bouchbika Z, Kouto H, Baruch-Hennequin V, Gornet JM, Munoz N, Cojean-Zelek I, Houdart R, Panis Y, Valleur P, Aparicio T, Maylin C, Hennequin C.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):574-80. doi: 10.1016/j.ijrobp.2011.07.031. Epub 2011 Nov 16.

PMID:
22099038
17.

Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.

Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A.

J Egypt Natl Canc Inst. 2007 Jun;19(2):147-57.

18.

Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.

Zhu Y, Sun Y, Hu S, Jiang Y, Yue J, Xue X, Yang L, Xue L.

BMC Gastroenterol. 2017 Mar 14;17(1):41. doi: 10.1186/s12876-017-0598-5.

19.

Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.

Cabau M, Luc G, Terrebonne E, Belleanne G, Vendrely V, Sa Cunha A, Collet D.

Am J Surg. 2013 Jun;205(6):711-7. doi: 10.1016/j.amjsurg.2012.08.009. Epub 2013 Feb 16.

PMID:
23422318
20.

Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T.

World J Surg Oncol. 2010 Apr 13;8:27. doi: 10.1186/1477-7819-8-27.

Supplemental Content

Support Center